This nonrandomized clinical trial examined whether psilocybin therapy is associated with changes in systemic markers of inflammation and mitochondrial stress in people with Parkinson disease who also have mood dysfunction.
The nonrandomized design limits causal inference; the absence of a control group makes it difficult to distinguish treatment effects from natural disease progression or placebo response; the full text is not yet publicly available (PMC embargo until 2027-10-21), so specific results and sample size cannot be confirmed.
Findings are not yet fully accessible; clinicians should await the full publication and peer review before drawing conclusions about psilocybin's effects on inflammation or mitochondrial stress in Parkinson disease.